Organogenesis Holdings Inc.

Listed Company

ORGOCIK 0001661181NasdaqAcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$564.17M

Net Income

$37.03M

Total Assets

$598.73M

Equity

$300.13M

Shares Out

128.67M

Op. Cash Flow

$-10.31M

ORGO$2.63−39.54% · past yearDBEQ Basic

Daily closing prices

Business

Organogenesis is a regenerative medicine company that develops, manufactures, and sells advanced wound care and surgical & sports medicine products. Its portfolio includes bioengineered skin substitutes (Apligraf, Dermagraft), placental allografts (Affinity, Novachor, NuShield), collagen-based products (PuraPly family, PuraForce), and pipeline candidates including ReNu for osteoarthritis. The company serves hospitals, wound care centers, ambulatory surgery centers, and physician offices primarily in the United States, with emerging international distribution.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	564	482	433	451	467
Cost of goods sold	138	116	106	—	—
Selling, general and administrative	326	295	270	284	250
Research and development	45	50	44	40	31
Write-down to fair value for asset held for sale	11	—	—	—	—
Impairment of property and construction	—	19	0	0	—
Write-down of capitalized internal-use software costs	—	4	0	0	—
Total operating expenses	519	483	421	324	281
Income (loss) from operations	45	−1	13	22	72
Interest income (expense), net	2	−2	−2	−2	—
Other income (expense), net	−5,000	20,000	57,000	−13,000	−13,000
Total other income (expense), net	2	−2	−2	−2	−9
Net income (loss) before income taxes	47	−3	10	20	63
Income tax benefit (expense)	−10	4	−5	−5	31
Net income (loss) and comprehensive income (loss)	37	861,000	5	16	94
Accretion of redeemable convertible preferred stock to redemption value	−540,000	−412,000	0	0	—
Cumulative dividend on redeemable convertible preferred stock	−11	−1	0	0	—
Undistributed earnings allocated to participating redeemable convertible preferred stock	−6	—	—	—	—
Net income (loss) attributable to common stockholders - basic	20	−937,000	5	16	95
Net income (loss) attributable to common stockholders - diluted	20	−937,000	5	16	—
Basic (per share)	0.16	−0.01	0.04	0.12	0.73
Diluted (per share)	0.15	−0.01	0.04	0.12	0.7
Basic (shares)	127	132	131	130	128
Diluted (shares)	130	132	133	132	134

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-03-31
Cash and cash equivalents	94	136	104	102	—
Restricted cash	652,000	580,000	498,000	812,000	—
Accounts receivable, net of allowance for credit losses of $17,467 and $9,576	217	110	82	89	—
Inventories, net	30	26	28	25	—
Asset held for sale (Note 8)	2	—	—	—	—
Prepaid expenses and other current assets	18	14	10	5	—
Total current assets	362	286	225	223	—
Property and equipment, net	104	89	116	102	—
Intangible assets, net	9	12	16	21	—
Goodwill	29	29	29	29	—
Operating lease right-of-use assets, net	56	37	40	43	—
Deferred tax asset, net	30	39	28	30	—
Other assets	9	5	6	2	—
Total assets	599	498	460	449	—
Current portion of finance lease obligations	9	1	1	—	—
Current portion of operating lease obligations - related party	4	4	8	3	—
Current portion of operating lease obligations	5	4	5	9	—
Accounts payable	32	29	31	32	—
Accrued expenses and other current liabilities	50	39	30	26	34
Total current liabilities	100	77	81	75	78
Finance lease obligations, net of current portion	13	718,000	2	—	—
Operating lease obligations, net of current portion - related party	28	8	12	20	—
Operating lease obligations, net of current portion	22	25	25	21	—
Other liabilities	1	894,000	1	1	—
Total liabilities	165	113	181	184	195
Commitments and contingencies (Note 20)	—	—	—	—	—
Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 shares authorized, issued and outstanding; liquidation preference of $142,217 and $131,387 at December 31, 2025 and 2024, respectively.	134	122	—	—	—
Preferred stock, $0.0001 par value; 870,000 shares authorized; none issued or outstanding	—	—	—	—	—
Common stock, $0.0001 par value; 400,000,000 shares authorized; 127,680,424 and 126,458,784 shares issued; 126,951,876 and 125,730,236 shares outstanding at December 31, 2025 and 2024, respectively	13,000	13,000	13,000	13,000	—
Additional paid-in capital	303	303	320	311	—
Accumulated deficit	−3	−40	−41	−45	−62
Total stockholders' equity	300	263	279	266	242
Total liabilities, redeemable convertible preferred stock, and stockholders' equity	599	498	460	449	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	15	14	10	6	—
Amortization of intangible assets	3	3	5	5	5
Reduction in the carrying value of right-of-use assets	8	8	8	7	6
Non-cash interest expense	375,000	394,000	427,000	434,000	346,000
Deferred interest expense	—	305,000	490,000	501,000	1
Deferred tax expense (benefit)	10	−11	2	2	−32
Loss on disposal of property and equipment	188,000	1	235,000	4	1
Loss on lease termination	—	0	559,000	0	—
Loss on extinguishment of term loan	—	215,000	0	0	—
Provision recorded for credit losses	8	4	1	2	3
Adjustment for excess and obsolete inventories	15	8	7	10	12
Stock-based compensation	13	11	9	7	4
Accounts receivable	−116	−32	6	−9	−29
Inventories	−18	−6	−8	−9	−9
Prepaid expenses and other current and other assets	−183,000	−3	−10	−378,000	−34,000
Operating leases	−8	−14	−8	−7	−6
Accounts payable	−528,000	−2	−108,000	3	4
Accrued expenses and other current liabilities	10	9	3	−12	9
Other liabilities	158,000	−1	91,000	72,000	−6
Net cash provided by (used in) operating activities	−10	14	31	25	62
Purchases of property and equipment	−14	−10	−24	−34	−31
Net cash used in investing activities	−14	−10	−24	−34	−31
Construction of landlord assets, net of tenant allowance	−14	—	—	—	—
Term loan repayments under the 2021 Credit Agreement	—	−67	−5	−3	−938,000
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	—	121	0	0	—
Payments for the repurchase of common stock	—	−25	0	0	—
Principal repayments of finance lease obligations	−1	−1	−485,000	−200,000	−3
Proceeds from the exercise of stock options	157,000	1	0	2	2
Payments of withholding taxes in connection with RSUs vesting	−2	−1	−332,000	−648,000	−737,000
Net cash provided by (used in) financing activities	−17	28	−6	−2	−1
Change in cash, cash equivalents and restricted cash	−42	32	1	−11	30
Cash paid for interest	—	5	5	3	6
Cash paid for income taxes	5	7	3	1	607,000
Cumulative effect adjustment for adoption of ASU No. 2016-13	—	0	615,000	0	—
Change in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	715,000	−432,000	841,000	2	—
Right-of-use assets obtained through operating lease obligations	27	5	6	1	54
Right-of-use assets obtained through finance lease obligations	22	0	3	0	—
Redeemable convertible preferred stock issuance costs included in accrued expenses	—	67,000	0	0	—
Prepaid rent reclassified to right-of-use assets	—	230,000	—	—	—
Landlord asset additions included in accounts payable and other liabilities, net of tenant allowances	3	—	—	—	—
Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock	11	2	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Organogenesis Holdings Inc.'s CIK number?

Organogenesis Holdings Inc.'s SEC CIK number is 0001661181 (1661181). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Organogenesis Holdings Inc.'s SEC filings?

All of Organogenesis Holdings Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Organogenesis Holdings Inc. last report earnings?

Organogenesis Holdings Inc. (ORGO) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001661181-26-000007). This is Organogenesis Holdings Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Organogenesis Holdings Inc.'s most recent earnings 8-K?

Organogenesis Holdings Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001661181-26-000007. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Organogenesis Holdings Inc.'s latest earnings 8-K →
Look up any company's CIK number →